NiCord®, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
NiCord® is a graft of stem/progenitor cells isolated and expanded from a portion of a single unit of umbilical cord blood and transplanted in combination with non-expanded cells. The portion of umbilical stem cells is expanded using Gamida Cell’s proprietary nicotinamide (NAM) technology, which leads to specific ex vivo expansion of functional CD34(+) cells. NiCord® is used to treat hematological malignancies and sickle cell disease and has been found to reduce the time of hematopoietic recovery and is capable of long term (>22 months) neutrophil and T-cell engraftment.
Read More
Product Information for
NiCord®, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access